Home/QLSF Biotherapeutics/Yonglei Shang, MD
YS

Yonglei Shang, MD

SVP, Antibody Discovery

QLSF Biotherapeutics

Therapeutic Areas

QLSF Biotherapeutics Pipeline

DrugIndicationPhase
QL401CancerPhase 1
QL325Acute Myeloid LeukemiaPhase 1
QL335Colorectal CancerPhase 1
QL535CancerIND-Enabling
QL555CancerPreclinical
QL615CancerPreclinical
QL301CancerPhase 1/2
QL415CancerPhase 1